When was NanoSyrinx founded?

NanoSyrinx was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is NanoSyrinx located?

NanoSyrinx is headquartered in Coventry, United Kingdom.

Who is the current CEO of NanoSyrinx?

Joe Healey of NanoSyrinx. They have also founded 1 company.

Which legal entities is NanoSyrinx associated with?

NanoSyrinx is associated with NANOSYRINX LTD.

How many employees does NanoSyrinx have?

As of Aug 31, 2026, the latest employee count at NanoSyrinx is 31.

Is NanoSyrinx a funded company?

NanoSyrinx is a funded company, having raised a total of $21.6M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 06, 2020.

How much is NanoSyrinx worth?

The latest valuation of NanoSyrinx is £***** as of Dec 01, 2022.

When was the latest funding round of NanoSyrinx?

NanoSyrinx's latest funding was a $***** Series A round on Sep 10, 2024, with participation from 6 investors.

Where does NanoSyrinx rank among its competitors?

NanoSyrinx ranks 5th amongst 280 active competitors, of which 79 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was YolTech, which secured $73.7M in May, 2026.

Who are the top competitors of NanoSyrinx?

NanoSyrinx's top competitors include Liquidia, Imbed Biosciences and Genedit. Among them, YolTech secured the most recent funding round in May, 2026.

NanoSyrinx - 2026 Company Profile, Team, Funding & Competitors

NanoSyrinx is a series A company based in Coventry (United Kingdom), founded in 2018 by Joe Healey and Nick R Waterfield. It operates as a Developer of targeted intracellular delivery platform for biological molecules. NanoSyrinx has raised $21.6M in funding from investors like Octopus Ventures, M Ventures and BGF, with a current valuation of £*****. The company has 280 active competitors, including 79 funded and 29 that have exited. Its top competitors include companies like Liquidia, Imbed Biosciences and Genedit.

Company Details

Developer of targeted intracellular delivery platform for biological molecules. The company focuses on enabling targeted, intracellular delivery of protein therapeutics. It creates a novel solution to the intracellular bioavailability problem. The company’s platform aims to unlock therapeutic opportunities within cells that are currently difficult to drug.

Website: www.nanosyrinx.com/
Social
Email ID: *****@nanosyrinx.com

Key Metrics

Founded Year

2018

Location

Coventry, United Kingdom

Stage

Series A

Total Funding

$21.6M in 5 rounds

Latest Funding Round

Series A, Sep 10, 2024, $*****

Post Money Valuation

£***** as on Dec 01, 2022

Investors

Octopus Ventures & 16 more

Ranked

5^th among 280 active competitors

Employee Count

31 as on Aug 31, 2026

Similar Companies

Liquidia & 371 more

View NanoSyrinx's full profile

NanoSyrinx is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
NANOSYRINX LTD CIN: 11595354 , United Kingdom, Active	Sep 28, 2018	-	18 (As on Dec 31, 2024)

NanoSyrinx has raised a total funding of $21.6M over 5 rounds. Its first funding round was on Mar 06, 2020. Its latest funding round was a Series A round on Sep 10, 2024 for $*****. 6 investors participated in its latest round. NanoSyrinx has 14 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of NanoSyrinx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2024	7001194	Series A	5690329	7926738	8392591	2758999
Jul 07, 2021	2376703	Seed	4533872	9552615	5206971	M Ventures & 4 more
Sep 30, 2020	2605723	Grant (prize money)	6048771	3626013	8992974	UK Innovation Science & Seed Fund & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of NanoSyrinx's funding rounds and investors

The founders of NanoSyrinx are Joe Healey and Nick R Waterfield. Joe Healey is the CEO of NanoSyrinx.

Here are the details of NanoSyrinx's key team members:

Joe Healey: Co-Founder & CEO of NanoSyrinx.
Contact Info: 1 email address
Nick R Waterfield: Co-Founder of NanoSyrinx.

View details of NanoSyrinx's Founder profiles and Board Members

NanoSyrinx's employee count trend

NanoSyrinx has 31 employees as of Aug 26. Here is NanoSyrinx's employee count trend over the years:

Uncover NanoSyrinx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NanoSyrinx include Liquidia, Imbed Biosciences and Genedit. Here is the list of Top 10 competitors of NanoSyrinx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
2nd	Imbed Biosciences 2010, Madison (United States), Series C	Provider of nanotech-based wound care products	$34.3M	Niterra, MassChallenge & 7 others	66/100
3rd	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	65/100
4th	Aera 2021, Boston (United States), Series B	Developer of genetic medicines across a wide range of therapeutic areas	$193M	Arch Venture Partners, Google Ventures & 3 others	62/100
5th	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Lilly, Octopus Ventures & 15 others	62/100
6th	Helex 2021, New York City (United States), Seed	Provider of next-generation gene-editing therapies	$6M	pi Ventures, IndieBio & 2 others	59/100
7th	Cour Pharma 2013, Chicago (United States), Series A	Developer of biotech nano-particles for immune diseases	$135M	Alpha Wave Global, Bristol-Myers Squibb & 6 others	57/100
8th	Starpharma 1996, United States, Public	Biotechnology company advancing dendrimer technology for improved patient health outcomes	-	The Australian health system, HHS	57/100
9th	YolTech 2021, Shanghai (China), Series C	Developer of gene editing and LNP delivery platforms for therapeutics	$133M	Decheng Capital, Loayal Valley Capital & 10 others	56/100
10th	Acorda 1995, Ardsley (United States), Acquired	Developer of therapies that restore neurological function	$66.5M	Saints Capital, Abn Amro & 16 others	56/100